The independent source for health policy research, polling, and news.
781 - 800 of 1,292 Results
For the seventh year in a row, Missouri will retain its lonely title as the only state without a statewide prescription drug monitoring program. Fears about privacy violations and gun control scuttled the bill yet again, leaving a pastiche of half-step measures in place to fill the void in the fight against prescription drug abuse.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Joanne Kenen of Politico, Jen Haberkorn of the Los Angeles Times and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss the latest news about the Trump administration’s effort to allow health care practitioners and organizations to refuse to provide care or refer patients for services that violate their conscience or religion. Also this week, the administration orders TV ads for prescription drugs to include list prices. And Tennessee wants free rein from the federal government to run its Medicaid program. Plus, Rovner interviews Joan Biskupic, author of a new book on Chief Justice John Roberts, about the behind-the-scenes negotiations that led to the 2012 ruling upholding the constitutionality of the Affordable Care Act.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
A study looked at who gets Suboxone prescriptions and found that whites are almost 35 times more likely to get the addiction treatment than African Americans.
America spends about as much on prescription drugs as all the revenues of the three big car makers combined. Tracking where the money goes is hard. PolitiFact has some charts to help.
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
The Congressional Budget Office report does clearly communicate that shifting to this type of health system would be a complicated process.
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
California Gov. Gavin Newsom claims that his state is “leading the nation in holding drug companies accountable and fighting prescription drug prices.” Is that really the case?
It’s as shady as it sounds.
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
After dozens of health care workers were charged with illegally prescribing opioids in Appalachia, local health agencies are trying to make sure chronic pain patients don't fall through the cracks.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
It’s "within spitting distance of something that’s true," said one health economist. But our fact check found it wasn't quite there.
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
© 2026 KFF